In preclinical and phase I and II trials of ALD518, a humanized monoclonal antibody targeting of IL-6 appeared to be well-tolerated and ameliorated NSCLC-related anemia and cachexia by controlling oncogene-associated inflammatory pathways [111]. This evidence concerns the gene IL6 and non-small cell lung carcinoma.